RE:RE:RE:Inflation Reduction Act (IRA) boosts biological drugs An important provision of the IRA is that biological drugs are given 13 years of market exclusivity (protection) versus 9 years of market exclusivity for small molecules. Biologics are large molecule "living drugs' while small molecules are chemically derived compunds (pills) with an active pharmaceutical ingredient. (API). Active pharmaceutical ingredients (APIs) are the chemical-based compounds that have produced mainly in the countries the USA, Europe, China, and India.
The passing of the IRA and corresponding provisions in the EU and the UK are to address the concerns over the production of chemical-based compounds in China and India and to re-establish the US and EU/UK as the power-houses of the life sciences and thus regain control over the health of their citizens. ONCY’s biologic pelareorep is well positioned to benefit from these global changes, particularly since Big Pharma, such as Pfizer and others, are shifting their focuses towards biological drugs (large molecules) and away from chemically-based compounds ( small molecules).